Cargando…

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease

BACKGROUND: Parkinson’s disease (PD) is one of the most common causes of dementia and motor deficits in the elderly. PD is characterized by the abnormal accumulation of the synaptic protein alpha-synuclein (α-syn) and degeneration of dopaminergic neurons in substantia nigra, which leads to neurodege...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valera, Elvira, Mante, Michael, Anderson, Scott, Rockenstein, Edward, Masliah, Eliezer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432827/ https://www.ncbi.nlm.nih.gov/pubmed/25966683 http://dx.doi.org/10.1186/s12974-015-0320-x

Ejemplares similares

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
por: Masliah, Eliezer, et al.
Publicado: (2011)

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
por: Spencer, Brian, et al.
Publicado: (2017)

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies
por: Hassen, Getaw Worku, et al.
Publicado: (2018)

APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis
por: Crews, Leslie, et al.
Publicado: (2009)

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
por: Spencer, Brian, et al.
Publicado: (2015)

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies
por: Price, Diana L., et al.
Publicado: (2016)

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
por: Spencer, Brian, et al.
Publicado: (2016)

Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
por: Iba, Michiyo, et al.
Publicado: (2020)

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
por: Rockenstein, Edward, et al.
Publicado: (2014)

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model
por: Xu, Jiqing, et al.
Publicado: (2016)

Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease
por: Desplats, Paula, et al.
Publicado: (2012)

A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick’s Disease and Fronto-Temporal Tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
por: Kim, Changyoun, et al.
Publicado: (2015)

Oligomer-prone E57K-mutant alpha-synuclein exacerbates integration deficit of adult hippocampal newborn neurons in transgenic mice
por: Regensburger, Martin, et al.
Publicado: (2017)

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
por: Mandler, Markus, et al.
Publicado: (2015)

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice
por: Spencer, Brian, et al.
Publicado: (2008)

The Temporal Expression Pattern of Alpha-Synuclein Modulates Olfactory Neurogenesis in Transgenic Mice
por: Schreglmann, Sebastian R., et al.
Publicado: (2015)

S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson’s disease
por: Sunico, Carmen R, et al.
Publicado: (2013)

Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer
por: Fields, Jerel, et al.
Publicado: (2013)

TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
por: Bender, Andreas, et al.
Publicado: (2013)

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2017)

Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2020)

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
por: Amschl, David, et al.
Publicado: (2013)

Tau Reduction Does Not Prevent Motor Deficits in Two Mouse Models of Parkinson's Disease
por: Morris, Meaghan, et al.
Publicado: (2011)

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity
por: Fields, Jerel A., et al.
Publicado: (2016)

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
por: Price, Diana L., et al.
Publicado: (2018)

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
por: Rabl, R., et al.
Publicado: (2017)

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
por: Kim, Changyoun, et al.
Publicado: (2018)

Peptides of Presenilin-1 Bind the Amyloid Precursor Protein Ectodomain and Offer a Novel and Specific Therapeutic Approach to Reduce ß-Amyloid in Alzheimer’s Disease
por: Dewji, Nazneen N., et al.
Publicado: (2015)

Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer's Disease
por: Spencer, Brian, et al.
Publicado: (2011)

Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
por: Kwon, Somin, et al.
Publicado: (2019)

Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity
por: Price, Diana L., et al.
Publicado: (2010)

Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease
por: Fang, Fang, et al.
Publicado: (2017)

Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice
por: Britschgi, Markus, et al.
Publicado: (2012)

Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
por: Kim, Changyoun, et al.
Publicado: (2021)

Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
por: Tsigelny, Igor F., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_82ncnuoo1u0dufb9fkttqoqj0l